https://scholars.lib.ntu.edu.tw/handle/123456789/634650
Title: | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations | Authors: | Sequist, Lecia V CHIH-HSIN YANG Yamamoto, Nobuyuki O'Byrne, Kenneth Hirsh, Vera Mok, Tony Geater, Sarayut Lucien Orlov, Sergey Tsai, Chun-Ming Boyer, Michael Su, Wu-Chou Bennouna, Jaafar Kato, Terufumi Gorbunova, Vera Lee, Ki Hyeong Shah, Riyaz Massey, Dan Zazulina, Victoria Shahidi, Mehdi Schuler, Martin |
Issue Date: | 1-Jun-2023 | Journal Volume: | 41 | Journal Issue: | 16 | Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Abstract: | The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634650 | ISSN: | 0732183X | DOI: | 10.1200/JCO.22.02547 |
Appears in Collections: | 醫學院附設癌醫中心醫院(臺大癌醫) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.